Duopharma Biotech Bhd (XKLS:7148) Cyclically Adjusted Book per Share: RM0.76 (As of Mar. 2026)


XKLS:7148 Duopharma Biotech Bhd XKLS:7148
83 GF Score
Price RM1.24
GF Value RM1.53
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Duopharma Biotech Bhd Cyclically Adjusted Book per Share?

Duopharma Biotech Bhd XKLS:7148 +2.48% 83 Cyclically Adjusted Book per Share is RM0.76 as of Mar. 2026. GuruFocus rates XKLS:7148 with a GF Score™ of 83/100 and a GF Value™ of RM1.53 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Duopharma Biotech Bhd's adjusted book value per share for the three months ended in Mar. 2026 was RM0.787. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is RM0.76 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Duopharma Biotech Bhd's average Cyclically Adjusted Book Growth Rate was 5.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 6.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 9.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Duopharma Biotech Bhd was 12.00% per year. The lowest was 6.70% per year. And the median was 9.60% per year.

As of today (2026-07-05), Duopharma Biotech Bhd's current stock price is RM1.24. Duopharma Biotech Bhd's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was RM0.76. Duopharma Biotech Bhd's Cyclically Adjusted PB Ratio of today is 1.63.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Duopharma Biotech Bhd was 6.68. The lowest was 1.58. And the median was 2.03.


Duopharma Biotech Bhd  (XKLS:7148) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Duopharma Biotech Bhd's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.24/0.76
=1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Duopharma Biotech Bhd was 6.68. The lowest was 1.58. And the median was 2.03.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Duopharma Biotech Bhd Cyclically Adjusted Book per Share Related Terms


Duopharma Biotech Bhd Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Duopharma Biotech Bhd's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duopharma Biotech Bhd Cyclically Adjusted Book per Share Chart

Duopharma Biotech Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.61 0.66 0.71 0.74

Duopharma Biotech Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.74 0.74 0.74 0.76

XKLS:7148 vs ZTS, UTHR, VTRS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Duopharma Biotech Bhd Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's Cyclically Adjusted PB Ratio falls into.


XKLS:7148
83GF Score
Duopharma Biotech Bhd XKLS:7148
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duopharma Biotech Bhd Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Duopharma Biotech Bhd's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.787/330.2130*330.2130
=0.787

Current CPI (Mar. 2026) = 330.2130.

Duopharma Biotech Bhd Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.515 241.018 0.706
201609 0.522 241.428 0.714
201612 0.524 241.432 0.717
201703 0.535 243.801 0.725
201706 0.533 244.955 0.719
201709 0.546 246.819 0.730
201712 0.553 246.524 0.741
201803 0.565 249.554 0.748
201806 0.551 251.989 0.722
201809 0.567 252.439 0.742
201812 0.545 251.233 0.716
201903 0.564 254.202 0.733
201906 0.556 256.143 0.717
201909 0.557 256.759 0.716
201912 0.581 256.974 0.747
202003 0.575 258.115 0.736
202006 0.620 257.797 0.794
202009 0.631 260.280 0.801
202012 0.684 260.474 0.867
202103 0.679 264.877 0.846
202106 0.652 271.696 0.792
202109 0.650 274.310 0.782
202112 0.663 278.802 0.785
202203 0.667 287.504 0.766
202206 0.670 296.311 0.747
202209 0.676 296.808 0.752
202212 0.688 296.797 0.765
202303 0.695 301.836 0.760
202306 0.701 305.109 0.759
202309 0.701 307.789 0.752
202312 0.714 306.746 0.769
202403 0.709 312.332 0.750
202406 0.721 314.175 0.758
202409 0.724 315.301 0.758
202412 0.737 315.605 0.771
202503 0.740 319.799 0.764
202506 0.765 322.561 0.783
202509 0.774 324.800 0.787
202512 0.788 324.054 0.803
202603 0.787 330.213 0.787

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of RM0.76 mean?
Duopharma Biotech Bhd (XKLS:7148) has a Cyclically Adjusted Book per Share of RM0.76 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Duopharma Biotech Bhd and its competitors.
Is Duopharma Biotech Bhd's Cyclically Adjusted Book per Share too high?
Duopharma Biotech Bhd's current Cyclically Adjusted Book per Share is RM0.76. Overall, Duopharma Biotech Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Duopharma Biotech Bhd's Cyclically Adjusted Book per Share of RM0.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Duopharma Biotech Bhd and its competitors. Duopharma Biotech Bhd's current Cyclically Adjusted Book per Share is RM0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.53, compared to a current price of RM1.24 — trading 19% below its estimated fair value. The current Cyclically Adjusted Book per Share is RM0.76. Duopharma Biotech Bhd's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Cyclically Adjusted Book per Share is RM0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?

Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued. The current stock price of RM1.24 is trading 19% below its estimated GF Value™ of RM1.53. GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:7148:

  • Cyclically Adjusted Book per Share: RM0.76
  • GF Value™: RM1.53 vs. price of RM1.24 (19% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Duopharma Biotech Bhd Business Description

Address Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, SGR, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
83GF Score

Get the complete analysis for XKLS:7148

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.24
Price
RM1.53
GF Value